EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Association of immune checkpoint inhibitors therapy with arterial thromboembolic events in cancer patients: A retrospective cohort study

Jie Zhu iD, Yue Chen, Yuanlong Zhang, Wei Wang, Yujue Wang, Zhuo Lu, Yulin Zhang, Haike Lei iD, Dairong Li, Bo Long, Haixia Liu

Cancer Medicine · 2023

DOI: 10.1002/cam4.6455 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Cancer Medicine, 2023. Verfasst von Jie Zhu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardio-Oncology, Chongqing University Cancer Hospital, Chongqing, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms, Thromboembolism. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chongqing Natural Science Foundation, Decision-making consultation and management innovation project in the Shapingba District of Chongqing.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs) have emerged as a standard treatment for various malignancies. However, research indicates blocking the immune checkpoint pathway may exacerbate atherosclerotic lesions.

Objectives

We aimed to investigate whether ICI therapy increases the risk of arterial thromboembolic events (ATEs).

Methods

A retrospective cohort study was conducted on patients with histologically confirmed cancer at our institution between 2018 and 2021, using the propensity score matching method. The primary endpoint was ATEs occurrence, comprising acute coronary syndrome, stroke/transient ischemic attack, and peripheral arterial thromboembolism. Subgroup analyses assessed whether the ICI treatment effect on ATEs varied over time by limiting the maximum follow‐up duration. Logistic regression analysis identified ATE risk factors in ICI‐treated patients.

Results

Overall, the ICI group ( n = 2877) demonstrated an ATEs risk 2.01 times higher than the non‐ICI group (RR, 2.01 [95% CI (1.61–2.51)]; p < 0.001). Subgroup analysis revealed no significant increase in ATEs risk for ICI‐treated patients within 1 year (Limited to a max 9‐month follow‐up, p = 0.075). However, ATEs risk in the ICI group rose by 41% at 1 year ( p = 0.010) and 97% at 4 years ( p ≤ 0.001). Age, diabetes, hypertension, peripheral atherosclerosis, atrial fibrillation, chronic ischemic heart disease, distant cancer metastasis, and ICI treatment cycles contributed to ATEs risk elevation in ICI‐treated patients.

Conclusion

ICI‐treated patients may exhibit a higher risk of ATEs, especially after 1 year of treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNeoplasmsThromboembolismHumansFemaleMaleRetrospective StudiesAgedMiddle AgedRisk FactorsAged, 80 and over

Stichwörter der Autor:innen

acute coronary syndromearterial thromboembolism eventsimmune checkpoint inhibitorsperipheral arterial thromboembolismretrospective cohort studystroketransient ischemic attack

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Cardio-Oncology, Chongqing University Cancer Hospital, Chongqing, China.
  • School of Medicine, Chongqing University, Chongqing, China.
  • Medical Record Management Department, Chongqing University Cancer Hospital, Chongqing, China.
  • Chongqing Cancer Multi-Omics Big Data Application Engineering Research Center, Chongqing University Cancer Hospital, Chongqing, China.
  • Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, China.

ORCID-Profile: Jie Zhu, Haike Lei

Förderung

  • Chongqing Natural Science Foundation
  • Decision-making consultation and management innovation project in the Shapingba District of Chongqing

Zitieren

APA

Zhu, J., Chen, Y., Zhang, Y., Wang, W., Wang, Y., Lu, Z., Zhang, Y., Lei, H., Li, D., Long, B., & Liu, H. (2023). Association of immune checkpoint inhibitors therapy with arterial thromboembolic events in cancer patients: A retrospective cohort study. Cancer Medicine. https://doi.org/10.1002/cam4.6455

Vancouver

Zhu J, Chen Y, Zhang Y, Wang W, Wang Y, Lu Z, et al. Association of immune checkpoint inhibitors therapy with arterial thromboembolic events in cancer patients: A retrospective cohort study. Cancer Medicine. 2023. doi:10.1002/cam4.6455

BibTeX
@article{Zhu2023,
  author = {Zhu, Jie and Chen, Yue and Zhang, Yuanlong and Wang, Wei and Wang, Yujue and Lu, Zhuo and Zhang, Yulin and Lei, Haike and Li, Dairong and Long, Bo and Liu, Haixia},
  title = {Association of immune checkpoint inhibitors therapy with arterial thromboembolic events in cancer patients: A retrospective cohort study},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6455}
}
Kostenlos starten →